Conference Coverage

Dedicated sickle cell center offers roadmap for care


 

EXPERT ANALYSIS FROM A MEETING ON SICKLE CELL DISEASE

– A care center for acute sickle cell pain management, which includes a dedicated emergency room and a daytime management unit in the hospital, decreased health system costs and the frequency of acute care visits by sickle cell patients, James Eckman, MD, reported at Sickle Cell Disease Symposium held by Carolinas Health Care System.

James Eckman, MD, is professor emeritus in hematology and medical oncology at the Winship Cancer Institute, Emory University School of Medicine, and former medical director of the Georgia Comprehensive Sickle Cell Center, Atlanta.

James Eckman, MD

By 2011, those numbers had dropped further, falling to less than four acute care visits per patient per year and less than 0.5 admissions per patient per year.

The results Dr. Eckman reported are based on 37 years of his experience at Grady Health System, which included setting up an emergency room dedicated to patients with sickle cell disease (SCD) and the launch of a tertiary care clinic in 1985. The Grady SCD database includes more than 4,500 patients, with about 1,000 adults active at any given time.

It’s the first 24-hour comprehensive acute care center for patients with sickle cell disease, according to Emory University.

“We really developed a model that was very cost effective for the management of this disease,” said Dr. Eckman, professor emeritus in hematology and medical oncology at Emory University. “We actually consistently turned a profit in our budget.”

Previously, SCD patients went to the regular emergency department for their acute pain crises, and they would often wait for hours without treatment. “You need to initiate treatment rapidly in these patients,” Dr. Eckman said. “It’s really unacceptable now what’s happening in our emergency rooms, where they have to wait 3, 4, or more hours to get treated while they’re in intolerable pain.”

In 2014, an expert panel issued guidelines for pain management in SCD calling for the initiation of pain treatment for acute crisis within 30 minutes of the patient’s arrival in the emergency department (JAMA. 2014 Sep 10;312[10]:1033-48). “Our goal is 20 minutes to have a complete assessment, get a laboratory draw, and have them on therapy,” he said. “And we were relatively successful in being able to do that.”

Each patient at the center was enrolled in a care management program consisting of 35 assessment and intervention elements. Assessment includes a complete medical evaluation, along with social and psychological evaluations. Intervention entails developing a detailed problem list – including medical, social, and psychological issues – a detailed management plan, and a social support plan. The initial assessment can take 4-8 hours.

For the first decade, the program tracked acute care visits and admissions in 166 continuing patients and saw dramatic declines in both. “The data only go through 1995, but they actually look exactly the same after 1995 all the way up to 2015,” Dr. Eckman said. “This sustained a really marked decrease in health care utilization.”

The program also identified a small group of patients – fewer than 75 out of a base of 1,000 – who accounted for 90% of visits, he said.

Although the Georgia experience is based on a dedicated care center for SCD, the results can be replicated without that type of dedicated infrastructure, Dr. Eckman said. “It is not the 24-hour acute care center,” he said. “It’s the carefully thought out and implemented comprehensive care plan by a multidisciplinary care team dedicated to care of the individuals with sickle cell disease that makes the difference.”

Dr. Eckman reported having no financial disclosures.

Recommended Reading

Sickle cell patients suffer discrimination, poor care – and shorter lives
MDedge Hematology and Oncology
CRISPR on the Senate health committee menu
MDedge Hematology and Oncology
Rigosertib produces better OS in MDS than tAML
MDedge Hematology and Oncology
Generic azacitidine approved in Canada
MDedge Hematology and Oncology
Drug can treat severely ill SCD patients, case suggests
MDedge Hematology and Oncology
Results support using MTD of HU in kids with SCA
MDedge Hematology and Oncology
CHMP recommends approval of romiplostim in kids
MDedge Hematology and Oncology
Drug receives orphan designation for treatment of PNH
MDedge Hematology and Oncology
Ferric citrate approved to treat iron-deficiency anemia
MDedge Hematology and Oncology
FDA approves wider use of hematology analyzer
MDedge Hematology and Oncology